KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Operations (2016 - 2025)

Travere Therapeutics' Cash from Operations history spans 15 years, with the latest figure at 60678000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 269.87% year-over-year to 60678000.0; the TTM value through Dec 2025 reached 37784000.0, up 115.91%, while the annual FY2025 figure was 37784000.0, 115.91% up from the prior year.
  • Cash from Operations reached 60678000.0 in Q4 2025 per TVTX's latest filing, up from 14317000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 60678000.0 in Q4 2025 to a low of 119005000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 43106600.0, with a median of 41012500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: surged 376.07% in 2021, then plummeted 666.59% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 88323000.0 in 2021, then rose by 13.16% to 76704000.0 in 2022, then plummeted by 50.98% to 115809000.0 in 2023, then surged by 69.16% to 35720000.0 in 2024, then skyrocketed by 269.87% to 60678000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Cash from Operations are 60678000.0 (Q4 2025), 14317000.0 (Q3 2025), and 4983000.0 (Q2 2025).